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Abstract
4-anilino quinazolines have been identified as inhibitors of HCV replication. The target of this class of compounds was
proposed to be the viral protein NS5A, although unequivocal proof has never been presented. A 4-anilino quinazoline
moiety is often found in kinase inhibitors, leading us to formulate the hypothesis that the anti-HCV activity displayed by
these compounds might be due to inhibition of a cellular kinase. Type III phosphatidylinositol 4-kinase a (PI4KIIIa) has
recently been identified as a host factor for HCV replication. We therefore evaluated AL-9, a compound prototypical of the 4-
anilino quinazoline class, on selected phosphatidylinositol kinases. AL-9 inhibited purified PI4KIIIa and, to a lesser extent,
PI4KIIIb. In Huh7.5 cells, PI4KIIIa is responsible for the phosphatidylinositol-4 phosphate (PI4P) pool present in the plasma
membrane. Accordingly, we observed a gradual decrease of PI4P in the plasma membrane upon incubation with AL-9,
indicating that this agent inhibits PI4KIIIa also in living cells. Conversely, AL-9 did not affect the level of PI4P in the Golgi
membrane, suggesting that the PI4KIIIb isoform was not significantly inhibited under our experimental conditions.
Incubation of cells expressing HCV proteins with AL-9 induced abnormally large clusters of NS5A, a phenomenon previously
observed upon silencing PI4KIIIa by RNA interference. In light of our findings, we propose that the antiviral effect of 4-
anilino quinazoline compounds is mediated by the inhibition of PI4KIIIa and the consequent depletion of PI4P required for
the HCV membranous web. In addition, we noted that HCV has a profound effect on cellular PI4P distribution, causing
significant enrichment of PI4P in the HCV-membranous web and a concomitant depletion of PI4P in the plasma membrane.
This observation implies that HCV – by recruiting PI4KIIIa in the RNA replication complex – hijacks PI4P metabolism,
ultimately resulting in a markedly altered subcellular distribution of the PI4KIIIa product.
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Introduction
Hepatitis C virus (HCV) is an enveloped, single-stranded RNA
virus classified as member of the Hepacivirus genus within the
Flaviviridae family. The 9.6 kb positive-sense RNA genome
contains a single open reading frame encoding a polyprotein of
about 3,000 amino acids, flanked by highly structured 59 and 39
untranslated (UTR) regions. Following its release into the
cytoplasm of the host cell, viral RNA is translated via an internal
ribosome entry site (IRES), giving rise to a single polypeptide that
is cleaved into 10 different mature protein products: Core, gpE1,
gpE2, p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B. HCV
RNA replication takes place in the cytoplasm, in association with a
virus-induced intracellular membrane structure termed ‘‘membra-
nous web’’, onto which NS proteins assemble to form the so-called
RNA replication complexes.
It is estimated that 3% of the world’s population are chronically
infected by the hepatitis C virus (HCV). Most infections become
chronic and over time evolve into chronic hepatitis. The most
unwanted complication of chronic hepatitis is cirrhosis, a massive
liver fibrosis, which can lead to liver failure and hepatocellular
carcinoma.
Since the discovery of hepatitis C virus (HCV) in the late 1980’s
much progress has been made in the understanding of the viral life
cycle of HCV. Nonetheless, to date no vaccines are available and
the current standard of care, involving lengthy treatment with a
combination of ribavirin and pegylated interferon-a (peg-IFN-a),
eradicates the infection in half of treated patients. A large effort
has been made in the past two decades in order to develop novel
anti-HCV therapies with greater efficacy. Two oral direct-acting
antiviral agents (DAA) targeting the HCV NS3/4 protease,
boceprevir and telaprevir, have recently reached the market and
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discovery of DAA focused almost exclusively on the best
characterized HCV enzymes required for viral replication – the
NS3/4A protease and the NS5B polymerase – in the past few
years the NS5A viral protein has been attracting more and more
attention as a target for drug development [1,2]. NS5A possesses
no known enzymatic activity. It is a multifunctional non-structural
protein important for viral replication [3–6] as well as viral
assembly [7–9]. It is a phosphoprotein consisting of three domains
[10]. Domain I is highly conserved and forms a dimeric structure
[11,12], whereas domains II and III are believed to adopt a
‘‘natively unfolded’’ conformation [13,14].
In recent years, several anti-HCV compounds identified using
cell-based replicon screens were indicated to target NS5A based
on the analysis of the mutations associated with emergence of
resistance in the replicon system [15–17].
The most studied series of these ‘‘NS5A inhibitors’’ is
represented by BMS-790052, an agent that is leading the field,
having demonstrated potent antiviral activity in clinical studies
[18]. Compounds in this class are characterized by a complex,
dimeric or pseudo-dimeric structure and a high molecular weight,
when compared with conventional ‘‘drug-like’’ small molecules
[17,19]. Resistance mutations against these compounds emerge
readily in domain I of NS5A [20], with the most recurrent of these
changes corresponding to variant of tyrosine at position 93 [20].
Although direct interaction with purified NS5A has not been
demonstrated, compelling reverse genetic experiments [20] as well
as molecular models [15,21] strongly support the notion that
NS5A is the direct target of these compounds.
A less characterized series of compounds, belonging to a
different chemical class, was also initially indicated to target NS5A
on the basis of the mutation pattern observed in resistant replicons
[21]. The common structural element of this latter class of
inhibitors is a 4-anilino quinazoline core. A representative member
of this class of compounds is A-831/AZD-2836, an experimental
antiviral agent that entered clinical trials but was later discontin-
ued due to the lack of adequate exposure [17]. For these agents,
the mutations reported to be associated with resistance were found
to be different from those expected for the NS5A inhibitor
described above, pointing to a different mechanism of action: a
few mutations were found at the C-terminal end of NS5A domain
I (E212D, L199F and T200P), whereas most mutations occurred
in NS5A domains II and III (P299L, S370P, V388D, V362A,
S390G and S370P). Additional mutations were also found in
NS4B (S258T) and NS5B (S76A) [17,21,22]. Reverse genetics
studies in which these mutations were reintroduced in the replicon,
however, did not recapitulate the resistant phenotype observed in
the original cellular clones [17], leaving thus the possibility open
that these compounds act through a different viral or cellular
target.
Interestingly, many kinase inhibitors, including some approved
antitumoral drugs (gefitinib, lapatinib, erlotinib) are 4-anilino
quinazoline derivatives [23–25]. Altogether, these considerations
led us to investigate whether the anti-HCV activity displayed by
these compounds might be due to inhibition of a cellular kinase.
Recently, several small-interfering RNA (siRNA) screening
campaigns have identified type III phosphatidylinositol 4-kinases
(PI4K) as crucial host factors for HCV replication. In particular,
PI4KIIIa was found to be required for HCV RNA replication in a
cell line- and genotype-independent manner, whereas the
requirement for the b isoform was observed to be less dramatic
and limited to Con-1 (genotype 1b) replicons [26–29]. It was
shown that the catalytic activity of PI4KIIIa is required to rescue
HCV replication in cells with a stable knock-down of PI4KIIIa.I n
addition, it has been proposed that NS5A stimulates PI4KIIIa
activity by direct interaction via domain I [30–32]. All these
observations taken together made us consider the phosphatidyli-
nositol 4-kinases a potential alternative candidate target for 4-
anilino quinazoline inhibitors of HCV replication.
In this paper, we present evidence that AL-9, a member of this
class of compounds previously reported to target NS5A, inhibits
PI4P formation by direct inhibition of phosphatidylinositol 4-
kinase IIIa (PI4KIIIa). In addition, we provide evidence that
pharmacological inhibition of PI4KIIIa with AL-9 results in
altered subcellular distribution of NS5A similar to that observed
after RNAi knock-down of the PI4KIIIa mRNA, strongly
supporting a mechanism of HCV inhibition mediated by the
inhibition of PI4KIIIa. Moreover, we show that HCV subverts
components of the phosphatidylinositol-4 phosphate (PI4P)
pathway to function in favor of its own life cycle, thereby
enriching the PI4P concentration in the membranous web while
depleting the plasma membrane PI4P pool.
Results
Compound AL-9 inhibits HCV replication in vitro
AL-9 is a member of 4-anilino quinazoline-containing HCV
replication inhibitors described previously ([21]; Figure 1). In
order to confirm its anti-HCV activity, we tested the effect of this
compound on HCV replication in Huh7.5 cells stably expressing
genotype 1b or 2a subgenomic replicons (Con1-SR and JFH-A4,
respectively). The EC50 values, calculated by measuring viral RNA
after incubation with AL-9 for three days, are reported in Table 1.
Replicon EC50 values for AL-9 were found to be 0.29 mM and
0.75 mM for genotype 1b and 2a, respectively. In order to prove
that AL-9 inhibits HCV replication not only in the context of a
HCV subgenomic replicon, but also in the context of the complete
viral life-cycle, we determined the inhibitory activity using the J6/
JFH-1 HCV virus. In this case, the EC50 value was found to be
1.2 mM, a figure comparable with the result obtained with
genotype 2a subgenomic replicon. CC50 values are shown for
Con1-SR, JFH-A4 and Huh7.5 cells, respectively. In summary,
Author Summary
It is estimated that 3% of the world’s population are
chronically infected by the hepatitis C virus (HCV). Most
infections become chronic and eventually evolve into
cirrhosis and hepatocellular carcinoma. Host factors are
interesting targets for anti-HCV therapies due to their
inherent high genetic barrier to resistance. Recently,
phosphatidylinositol 4-kinase a (PI4KIIIa) has been identi-
fied as a crucial host factor for HCV replication. Many
different pathogens, including HCV, subvert components
of the phosphatidylinositol-4 phosphate (PI4P) pathway to
function in favor of their own life cycle. In this paper, we
show that HCV dramatically alters cellular PI4P metabolism
and distribution, resulting in the enrichment of PI4P in the
membranous web required for viral replication with a
concomitant decrease of PI4P in the plasma-membrane.
Moreover, we demonstrate that 4-anilino quinazolines,
antiviral agents previously believed to target HCV NS5A,
do in fact inhibit PI4P formation by inhibition of PI4KIIIa.
This compound class is a promising lead for the
development of a novel antiviral therapy based on PI4KIIIa
inhibition. Specific PI4KIIIa inhibitors would also be
important research tools required for a deeper under-
standing of the functions and regulation of PI4P.
Anilino Quinazoline HCV Inhibitors Target PI4KIIIa
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sub-micromolar to low micromolar range in the absence of
significant cytotoxic effects.
AL-9 is an inhibitor of PI4KIIIa
In the following experiment, we investigated whether AL-9
inhibits the purified type III phosphatidylinositol 4-kinases
PI4KIIIa and PI4KIIIb (Figure 2). Both enzymes were inhibited
by AL-9 with a five-fold preference for PI4KIIIa (IC50 of 0.57 mM
and 3.08 mM, respectively). This result demonstrates that AL-9
inhibits type III PI4 kinases in vitro at concentrations similar to
those required for its anti-HCV activity, displaying a moderate
selectivity for the a over the b isoform. We also tested the activity
of AL-9 on two class I PI3-kinases (p110a and p110b). While PI3-
kinase p110a was inhibited with an IC50 of 1.1 mM, the potency of
AL-9 for PI3-kinase p110b was significantly lower (40% inhibition
@10 mM, data not shown).
Our hypothesis is that AL-9 inhibits HCV replication via
inhibition of PI4KIIIa. Thus, we wanted to assess whether AL-9
also inhibited PI4KIIIa in living cells. To this aim, we needed to
set up an assay that allowed us to monitor the activity of this kinase
in intact cells. PI4KIIIa is primarily localized to the ER, whereas
PI4KIIIb is localized to the Golgi membranes [33]. It was shown
that PI4KIIIb contributes to the synthesis of PI4P at the Golgi
membranes [34,35]. Subcellular localization of the enzymes,
however, does not always coincide with their function. Thus,
PI4KIIIa, considered to be an ER-resident enzyme, has previously
been shown to be critical for the generation and maintenance of
the plasma membrane PI4P pool during phospholipase C
activation and Ca2 signaling in HEK-293 or Cos-7 cells [35,36]
as well as in resting Cos-7 cells [37]. Whether PI4KIIIa is
responsible for the maintenance of the plasma membrane PI4P
pool under normal cell culture conditions in hepatoma cells is
currently not known. Hammond et al [37] have developed
immunocytochemical techniques that enable selective staining of
the PI4P pool present in the plasma membrane (plasma
membrane staining protocol) or in the intracellular membranes
(Golgi staining protocol), respectively. We used this technique, in
combination with RNA gene silencing or pharmacological
inhibition, to decipher which of the type III enzymes participates
in the synthesis of the Golgi- or plasma membrane PI4P-pools in
Huh7.5 hepatoma cells.
To address which type III PI4 kinase is responsible for the
synthesis of the different cellular PI4P pools, Huh7.5 cells were
treated with siRNAs targeting PI4KIIIa, PI4KIIIb or an unrelated
siRNA (mock-siRNA) as described in the Materials and Methods
section. Immunoblots assays show specific knockdown of PI4KIIIa
or PI4KIIIb by their corresponding siRNAs (Figure 3C). Three
days after siRNA treatment, PI4P was revealed either by the
plasma membrane staining protocol (Figure 3A, upper panel) or
by the Golgi membrane staining protocol (Figure 3A, lower panel).
In cells treated with the unrelated siRNA (mock-siRNA), PI4P was
detected both in the plasma membrane and in intracellular
membranes. Intracellular PI4P was localized primarily in the
Golgi membranes, as judged by the colocalization with the Golgi
marker giantin. Silencing of PI4KIIIa resulted in a significant
decrease of the PI4P level in the plasma membrane. Concomi-
tantly with the decrease in the plasma membrane PI4P levels, we
consistently observed a pronounced increase of PI4P level in the
Golgi membrane following PI4KIIIa knockdown. In the case of
Figure 1. Chemical structure of AL-9. For the synthetic pathway
and procedure see Supporting Information.
doi:10.1371/journal.ppat.1002576.g001
Table 1. List of EC50 values of AL-9 for different HCV
genotypes.
genotype EC50 (mM) CC50 (mM)
Con1-SR 1b 0.29 (+/20.09) 29.3 (+/22.8)
JFH-A4 2a 0.75 (+/20.15) 18.9 (+/23.2)
Huh7.5+J6/JFH-1 HCV 2a 1.2 (+/20.37) 25.1 (+/24.6)*
Huh7.5 cells replicating subgenomic replicons of genotype 1b or 2a (Con1-SR
and JFH-A4, respectively) or Huh7.5 cells infected with the chimeric virus J6/JFH
were treated with AL-9 for three days and intracellular viral RNA was measured
by real time PCR. The data are representative of at least three independent
experiments, and the standard deviations are shown.
*CC50 measured in uninfected Huh7.5 cells.
doi:10.1371/journal.ppat.1002576.t001
Figure 2. Inhibitory dose-response curve of AL-9 for purified
PI4KIIIa and PI4KIIIb. The enzymes were preincubated for 10 min
with the indicated concentrations of AL-9 or DMSO and the reaction
was started by addition of 100 mM ATP and 150 mM PI:PS substrate as
described in Materials and Methods. Activity, measured as conversion of
ATP to ADP, is expressed as percent of the DMSO control. Shown is a
representative experiment of three independent experiments per-
formed in duplicate. IC50 and SD of PI4KIIIa and PI4KIIIb are indicated.
doi:10.1371/journal.ppat.1002576.g002
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PLoS Pathogens | www.plospathogens.org 3 March 2012 | Volume 8 | Issue 3 | e1002576Figure 3. RNA interference analysis of PI4P production in Huh7.5 cells. Huh7.5 cells were treated with irrelevant (mock) siRNA or siRNA
targeting PI4KIIIa or PI4KIIIb as detailed in Materials and Methods. The data were collected three days after initial siRNA transfection. (A) Confocal
microscopy images of Huh7.5 cells treated with PI4KIIIa siRNA, PI4KIIIb siRNA or mock siRNA. Cells were fixed and stained as described in Materials
and Methods. PI4P (green) localized to the plasma membrane (PM) was detected using the plasma membrane staining protocol (upper panel) [37].
Nuclei were stained by the Hoechst dye (blue). PI4P in the intracellular membranes (IM) was revealed using the Golgi staining protocol (lower panel).
Together with PI4P, Golgi membranes were stained with the Golgi marker giantin (red). Colocalization of PI4P with Golgi membranes results in yellow
color. (B) Quantification of PI4P levels by immunofluorescence analysis. Changes in mean fluorescence intensity relative to the control (mock siRNA)
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PLoS Pathogens | www.plospathogens.org 4 March 2012 | Volume 8 | Issue 3 | e1002576PI4KIIIb knockdown, we observed a ,30% decrease of Golgi
membrane PI4P level, whereas the PI4P levels of the plasma
membrane remained substantially unaffected (Figure 3B).
These results are in line with the previously reported role for
PI4KIIIa in maintaining the PI4P plasma membrane pool [35–
37] and confirm the importance of PI4KIIIb for the synthesis of at
least part of the Golgi membrane PI4P [34,35]. We also observed
that decreased expression of PI4KIIIa resulted in an unexpected
increase in the level of the Golgi membrane pool (Figure 3A),
suggesting a complex level of cross-talk between the cellular type
III PI4 kinases in maintaining the physiological PI4P levels at the
Golgi membrane, at least in our experimental model.
In order to confirm and extend the results described above, we
utilized a known pharmacological inhibitor of the type III PI4
kinases. PIK93 was previously exploited to distinguish between the
roles of the two PI4KIII isoforms [38,39]. In particular, a
concentration of 0.5 mM PIK93 is expected to affect only PI4KIIIb,
whereas30 mM PIK93 shouldinhibitboth PI4KIIIb and PI4KIIIa.
Thus, Huh7.5 cells were treated with 0.5 mMo r3 0mM PIK93 or
with DMSO as control. After two hours of incubation, PI4P was
revealed either by the plasma membrane staining protocol
(Figure 4A, upper panel) or by the Golgi staining protocol
(Figure 4A, lower panel). PI4P levels associated with the Golgi
membranes decreased by ,25% after incubation with 0.5 mM
PIK93 (Figure 4B). This is in line with PI4KIIIb contributing to the
production of PI4P present in the Golgi membranes (PI4KIIa,
another contributor of Golgi-localized PI4P is not inhibited by
PIK93 [38,39]). Increasing PIK93 concentration to 30 mM further
increased the inhibition of the intracellular membrane PI4P pool, to
,65% (Figure 4B). Thiscould be due to a more complete inhibition
of PI4KIIIb; however, based on this experiment, we cannot rule out
a contribution of PI4KIIIa activity to the maintenance of the Golgi
membrane PI4P pool. In contrast to what observed in the Golgi-
associated membranes, the plasma membrane PI4P level was not
significantly affected upon incubation with 0.5 mM PIK93, but
decreased by nearly 50% after incubation with 30 mM of PIK93
(Figure 4B). Combined with the RNAi experiments described
above, these results support the notion that, in Huh7.5 cells,
PI4KIIIa is involved in the maintenance of the plasma membrane
PI4P pool, whereas PI4KIIIb is at least partly responsible for the
maintenance of the Golgi membrane PI4P pool.
We then evaluated the PI4K inhibitory activity of AL-9 in
Huh7.5 cells using the same methodology. Briefly, Huh7.5 cells
were incubated either with DMSO or with increasing concentra-
tion of AL-9 (1, 2, 4 or 8 mM) for two hours (Figure 5A).
Treatment with AL-9 gradually reduced the amount of PI4P in the
plasma membrane (Figure 5B). Conversely, the concentration of
PI4P in the Golgi-associated membranes remained substantially
unaltered up to the highest AL-9 concentration used (Figure 5B).
In all, the results described above suggest that AL-9 inhibits
PI4KIIIa also in living cells, while not appreciably affecting the
activity of PI4KIIIb. This is in line with the selectivity for
PI4KIIIa over PI4KIIIb observed in the biochemical assays.
HCV alters the intracellular and plasma membrane
distribution of PI4P
Viral infection induces modification of intracellular membrane
structures [40] and, for some RNA viruses including HCV, it has
been shown that these induced membranous structures are highly
enriched for PI4P [32,41]. Before testing the activity of AL-9 in
HCV-infected cells, we wanted to know what the impact of HCV
on cellular membrane structures was, with special regard to the
subcellular membrane distribution of PI4P.
Naı ¨ve Huh7.5 cells or cells actively replicating the genotype 2a or
1b HCV subgenomic replicon were investigated for their PI4P
concentration in internal membranes or plasma membranes,
respectively (Figure 6A). As previously shown, cells expressing the
HCV replicon form a membranous web that is highly enriched for
PI4P (Figure 6A, lower panel). The level of PI4P in these virus-
specific membrane structures is markedly higher in JFH-A4 cells,
containing the very efficient genotype 2a JFH-1 replicon, compared
to the Con1-SR cells, which are based on the genotype 1b Con1
replicon, possibly mirroring the different RNA replication efficien-
cy. It is well established that the kinase responsible for the
production of the PI4P pool present in these structures is PI4KIIIa.
In the current model, PI4KIIIa interacts with the viral protein
NS5A, leading to up-regulation of the kinase activity and
accumulation of PI4P in the virus-specific membranous web [30–
32]. Conversely, the results shown in Figures 3–5 suggest that – in
absence of viral replication – a major function of PI4KIIIa is the
synthesis of the PI4P pool in the plasma membrane. We therefore
asked ourselves whether the presence of HCV could not only
influence distribution and enrichment of PI4P in internal
membranes, but also alter the PI4P plasma membrane pool. In
Figure 6A, we show that, concomitantly with the increase of PI4P in
the internal membranes (lower panel), HCV replication promotes a
marked decrease of PI4P concentration in the plasma membrane
(upper panel). Relative quantification of the PI4P levels in the
different experimental conditions is shown in Figure 6B. This
experiment demonstrates that the presence of HCV causes a
dramatic change of PI4P localization in cellular membranes,
whereby the increase of PI4P concentration in the virus-specific
membranous structures appears to be accompanied by a depletion
of the PI4P pool normally present in the plasma membrane.
We next investigated whether HCV-associated changes in PI4P
distribution could be reverted upon cure of the HCV replicon by
specific inhibitors. We treated JFH-A4 cells for two weeks either
with the HCV RdRP inhibitor HCV-796 or with the HCV NS3/
4A protease inhibitor MK-5172 and followed PI4P localization in
internal membranes and in the plasma membrane (Figure 7).
Independent of the type of inhibitor used, the result shows that the
HCV-induced PI4P-enriched membranous web in JFH-A4 cells
disappeared upon suppression of HCV replication and that the
intracellular PI4P localization returned to the Golgi-localization as
observed in the naı ¨ve Huh7.5 cells (left column). In parallel, the
plasma membrane concentration of PI4P increases to the levels
observed in naı ¨ve cells (middle column). NS5A staining (right
column) as well as real-time RT-PCR (not shown) indicated that
the prolonged treatment with HCV-inhibitor led to complete and
stable suppression of viral protein expression and undetectable
level of HCV RNA. Thus, removal of HCV RNA brings PI4P
synthesis and distribution back to a level comparable to naı ¨ve
Huh7.5 cells. It is worth of note, however, that the previous
presence of HCV replicons in the cured cells induced some
irreversible morphological changes of unknown nature, such as a
smaller cell size.
are shown. Four randomly picked fields were analyzed per each condition, as described in Materials and Methods. Data are presented as averages 6
SEM. *, p,0.05; **, p,0.01. (C) Immunoblot analysis of protein expression after RNAi silencing. Lysates prepared from Huh7.5 cells transfected with
irrelevant siRNA (mock), PI4KIIIa siRNA (PIKA) or PI4KIIIb siRNA (PIKB) were analyzed by immunoblotting with PI4KIIIa, PI4KIIIb or b-actin antibodies as
indicated in the figure. Positions of the protein molecular weight markers are shown on the left side.
doi:10.1371/journal.ppat.1002576.g003
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PLoS Pathogens | www.plospathogens.org 5 March 2012 | Volume 8 | Issue 3 | e1002576Figure 4. Effect of PIK93 on Golgi or plasma membrane PI4P in Huh7.5 cells. (A) Confocal microscopy images of Huh7.5 cells incubated with
DMSO (left column), 0.5 mM PIK93 (central column) or with 30 mM PIK93 (right column) for 2 hours prior to fixation and staining as described in
Materials and Methods. PI4P (green) localized to the plasma membrane (PM) was detected using the plasma membrane staining protocol (upper
panel) [37]. Nuclei were stained by the Hoechst dye (blue). PI4P in the intracellular membranes (IM) was revealed using the Golgi staining protocol
(lower panel). Together with PI4P, Golgi membranes were stained with the Golgi marker giantin (red). Colocalization of PI4P with Golgi membranes
results in yellow color (zoomed sections are indicated by a yellow square). (B) Quantification of PI4P levels by immunofluorescence analysis. Changes
in mean fluorescence intensity relative to the control (DMSO) are shown. Four randomly picked fields were analyzed per each condition.
Normalization was performed as detailed in Materials and Methods. Data are presented as averages 6 SEM. *, p,0.05; **, p,0.01; ***, p,0.001.
doi:10.1371/journal.ppat.1002576.g004
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PLoS Pathogens | www.plospathogens.org 6 March 2012 | Volume 8 | Issue 3 | e1002576AL-9 inhibits PI4KIIIa in HCV-replicating cells
We have shown that PI4KIIIa is inhibited by AL-9 in naı ¨ve
Huh7.5 cells. As discussed above, in HCV-replicating cells, the
kinase activity of PI4KIIIa is up-regulated by a direct protein-
protein interaction with the viral protein NS5A [30,32]. In the
following experiment (Figure 8), we explored whether AL-9 is able
to inhibit PI4KIIIa also in this context. JFH-A4 cells were
incubated with increasing concentration of AL-9 for 4 hours and
PI4P concentration in the HCV membranous web was followed
by immunostaining (Golgi staining protocol). Treatment of cells
with AL-9 lead to clear inhibition of PI4P accumulation in the
HCV membranous web. Incubation with 8 mM AL-9 depleted as
much as 70% of the PI4P present in the intracellular membranes
of replicon-containing cells. This result confirms that AL-9 inhibits
Figure 5. AL-9 inhibits PI4KIIIa in Huh7.5 cells. (A) Confocal microscopy images of Huh7.5 cells treated for 2 hours with DMSO (left column) or
with 1, 2, 4 or 8 mM of AL-9 (columns 2 to 5). PI4P (green) localized to the plasma membrane (PM) was detected using the plasma membrane staining
protocol (upper panel) [37]. Nuclei were stained by the Hoechst dye (blue). PI4P in the intracellular membranes (IM) was revealed using the Golgi
staining protocol (lower panel). Together with PI4P, Golgi membranes were stained with the Golgi marker giantin (red). Colocalization of PI4P with
Golgi membranes results in yellow color (zoomed sections are indicated by a yellow square). (B) Quantification of PI4P levels by immunofluorescence
analysis. Changes in mean fluorescence intensity relative to the control (DMSO) are shown. Four randomly picked fields were analyzed per each
condition. Normalization was performed as detailed in the Materials and Methods. Data are presented as averages 6 SEM. **, p,0.01; ***, p,0.001.
doi:10.1371/journal.ppat.1002576.g005
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PLoS Pathogens | www.plospathogens.org 7 March 2012 | Volume 8 | Issue 3 | e1002576Figure 6. HCV impacts subcellular PI4P distribution. (A) Huh7.5 cells, JFH-A4 and Con1-SR cells were analyzed by confocal microscopy for the
presence of PI4P (green) in the plasma membranes (PM, upper panel) or in the intracellular membrane (IM, lower panel) using the protocols
described in Materials and Methods. Nuclei were stained by the Hoechst dye (blue). For internal membrane staining, giantin (red) was used as a
specific marker for Golgi membranes. (B) Quantification of PI4P levels by immunofluorescence analysis. Changes in mean fluorescence intensity
relative to the control (Huh7.5 cells) are shown. Four randomly picked fields were analyzed per each condition. Normalization was performed as
detailed in Materials and Methods. Data are presented as averages 6 SEM. *, p,0.05; **, p,0.01; ***, p,0.001.
doi:10.1371/journal.ppat.1002576.g006
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PLoS Pathogens | www.plospathogens.org 8 March 2012 | Volume 8 | Issue 3 | e1002576Figure 7. Reversibility of HCV-induced changes in PI4P subcellular distribution. JFH-A4 cells were incubated for 14 days with the HCV
RdRP inhibitor HCV-796 (2 mM) or the HCV NS3/4A protease inhibitor MK-5172 (0.2 mM). Cure from HCV was controlled by detection of NS5A with a
specific NS5A antibody (red, right column). As control, untreated Huh7.5 cells or JFH-A4 cells were used. Cells were fixed and PI4P (green) was
detected in the internal membranes (IM, left column) or in the plasma membrane (PM, central column). For internal membrane staining giantin (red)
was used as a specific marker for Golgi membranes. Nuclei were stained by the Hoechst dye (blue).
doi:10.1371/journal.ppat.1002576.g007
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suggests that this inhibition could be responsible for the observed
antiviral effect. Since AL-9 has anti-HCV activity in the
concentration range used here, longer incubation of HCV
replicons with AL-9 results in inhibition of HCV RNA- and
protein-synthesis. As a consequence, the PI4P-enriched HCV
membranous web would disintegrate. In this case loss of PI4P in
the internal membranes could be not a direct consequence of
PI4KIIIa inhibition, but a consequence of disintegration of the
HCV membranous web.
In order to rule out this possibility, we checked localization of
NS5A, a presumed marker for HCV replication sites, after 4 hours
of incubation with AL-9. Localization of NS5A does not change,
suggesting that AL-9 does not significantly change the structure of
the HCV membranous web upon 4 hours of treatment. Moreover,
incubating the same replicon cells for 4 hours with HCV-796, an
HCV polymerase inhibitor, did not lead to appreciable depletion
of the membranous web PI4P pool indicating that the loss of PI4P
in the HCV-induced intracellular membranes is the direct
consequence of inhibition of PI4KIIIa, and not the consequence
of inhibition of HCV replication. Additional evidence is provided
in the experiment below, in which expression of the HCV
polyprotein, and consequently formation of a membranous web,
was driven by cDNA plasmid rather than by autonomously
replicating HCV RNA.
PI4KIIIa inhibition by AL-9 alters sub-cellular distribution
of NS5A
It was previously shown that knock-down of PI4KIIIa
expression by RNAi resulted in the production of large NS5A
clusters. This was achieved in an experimental setting where the
HCV polyprotein was expressed from DNA constructs, thus
avoiding potential confounding effects due to inhibition of HCV
RNA replication [27,32]. We wanted to assess whether pharma-
cological inhibition of PI4KIIIa kinase activity would lead to
similar effects on NS5A subcellular localization. Thus we followed
the effect of AL-9 on NS5A localization after transient DNA
transfection in Huh7-Lunet/T7 cells with a plasmid expressing
genotype 2a nonstructural proteins NS3-NS5B under the control
of a T7 promoter [42]. Cells were treated either with DMSO
(upper panels) or with 8 mM AL-9 (lower panels) for 2, 8 or
16 hours and localization of NS5A as well as PI4P were followed
by indirect fluorescence microscopy (Figure 9). Cells successfully
transfected with the HCV polyprotein expressed NS5A and
induced the PI4P-enriched membranous web. After 8 hours of
treatment with AL-9, changes in NS5A localization in form of
larger clusters become visible. At the same time, PI4P concentra-
tion in the membranous web started to decrease. After 16 hours of
incubation with AL-9, NS5A was concentrated almost exclusively
in large clusters. At this time-point, PI4P in the internal
membranes had completely vanished.
In summary, this experiment shows that, in cells expressing the
HCV polyprotein from cDNA, prolonged treatment with AL-9
results in a redistribution of NS5A into large clustered structures
with high resemblance to the structures previously observed after
silencing of the PI4KIIIa gene by RNAi [27,32]. Concomitantly,
we observed a depletion of the PI4P pool present in the HCV-
induced membranous structures. These results indicate that the
catalytic activity of PI4KIIIa is directly or indirectly required for
the proper localization of HCV NS5A protein into the
membranous web. Furthermore, the experiment just described
lands additional support to the notion that the antiviral effect of
AL-9 is mediated by the inhibition of PI4KIIIa.
Discussion
In the present paper, we show that a compound belonging to
the class of 4-anilino quinazoline inhibitors of HCV replication is
an inhibitor of PI4KIIIa, a cellular lipid kinase required for viral
replication.
PI4KIIIa belongs to the family of type III phosphatidylinositol
4-kinases, enzymes that catalyze the conversion of phosphatidy-
linositol to phosphatidylinositol 4-phosphate (PI4P). PI4P is the
most abundant monophosphorylated inositol phospholipid in
mammalian cells and the importance of this phospholipid is just
started to be unraveled [43]. In addition to playing important roles
in intracellular signaling and membrane trafficking, phosphatidy-
linositol lipids and their metabolizing enzymes are also exploited
by many different viruses in order to transform cellular
membranes in structures supporting their replication [40,44,45].
PI4KIIIb was shown to be a host factor required for enterovirus
replication [41], whereas several reports have demonstrated that
PI4KIIIa is crucial for HCV replication [26–29]. Owing to the
importance of this pathway, the need for specific inhibitors of
PI4III kinases is increasing. Only recently, some enviroxime-like
compounds with antiviral activity against enterovirus have been
demonstrated to target PI4KIIIb. One of these agents is a very
specific inhibitor of the b-isoform of the type III PI4-kinases [46].
So far, no such compound exists for the PI4KIII-a isoform. A
commonly used inhibitor for type III phosphatidylinositol 4-
kinases is PIK93, which has originally been designed to inhibit
class I PI3-kinases [38]. This compound allows differential
inhibition of PI4KIIIb alone or PI4KIIIa and PI4KIIIb together
depending on the concentration used. In this paper, we show that
a 4-anilino quinazoline derivative, termed AL-9 (Figure 1 and
Figure S1), is able to inhibit PI4KIIIa in a test tube as well as in
living cells. AL-9 inhibited purified PI4KIIIa, with a moderate
(,5-fold) selectivity over the b isoform (Figure 2). In cell culture,
we observed that treatment with AL-9 efficiently inhibits the
maintenance of the plasma membrane PI4P pool in Huh7.5 cells
while not significantly affecting the Golgi membrane pool at the
highest concentration used (Figure 5). This finding is in line with
the moderate selectivity observed in the biochemical assay. Thus,
AL-9 represents a lead candidate for the development of more
potent and more specific inhibitors of PI4KIIIa.
Anti-HCV compounds of the 4-anilino quinazoline class were
previously assumed to exert their antiviral effect via inhibition of
the viral protein NS5A. This conclusion rested on analysis of
the mutations found in the HCV replicon in association with
Figure 8. AL-9 inhibits PI4KIIIa in HCV-replicating cells. (A) JFH-A4 cells were treated with DMSO or AL-9 for 4 hours and internal membranes
were stained for PI4P (green) and the Golgi marker giantin (red) using the Golgi staining protocol, as described in Materials and Methods. DMSO or
AL-9 concentrations are indicated within the image. Alternatively, cells were stained for NS5A as described in Materials and Methods (indicated as
NS5A). Nuclear DNA was stained with Hoechst dye (blue). PI4KIIIa, associated with the HCV-associated membranous web is inhibited by AL-9. The
decrease of PI4P is not due to inhibition of the HCV replication indicated by unchanged NS5A expression and localization (lower panel). (B)
Quantification of PI4P levels by immunofluorescence analysis. Changes in mean fluorescence intensity relative to the control (DMSO) are shown. Four
randomly picked fields were analyzed per each condition. Normalization was performed as detailed in Materials and Methods. Data are presented as
averages 6 SEM. **, p,0.01; ***, p,0.001.
doi:10.1371/journal.ppat.1002576.g008
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anilino quinazolines were localized mainly in NS5A, in triplets that
occurred all in NS5A or appeared concomitant with changed in
NS4B or NS5B [17,22] (see also Introduction). Reverse genetic
experiments, in which these mutations were reintroduced in the
replicon (single, double and triple combinations), however, did not
support a role for these mutations in conferring resistance to 4-
anilino quinazolines [17]. In order to assess whether the reported
mutations conferred any level of resistance to AL-9, we
independently performed reverse genetics studies in which selected
mutations triplets, reported to be associated with the higher level
of resistance, were reintroduced in a genotype 1b replicon with the
Figure 9. Inhibition of PI4KIIIa by AL-9 induces the formation of large NS5A clusters. Huh7-Lunet/T7 cells were transiently transfected
with the plasmid pTM-NS3-5B which expresses the HCV nonstructural proteins under the control of the T7 RNA polymerase promoter. Cells were
treated with DMSO (upper panels) or 8 mM AL-9 (lower panels) for 2, 8 or 16 hours and were then stained for NS5A (red) and PI4P (green) using the
Golgi staining protocol as described in Materials and Methods. Nuclear DNA was stained with the Hoechst dye (blue). Zoomed sections are indicated
by a yellow square. Long incubation with AL-9 (8–16 hours) results in increased NS5A clustering and concomitantly a decrease of PI4P in the internal
membranes.
doi:10.1371/journal.ppat.1002576.g009
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resistance study (Figure S2). These mutation triplets are: FAG:
L199F+V362A+S390G (NS5A), DLD: E212D+P299L+V388D
(NS5A), and PPA: T200P+S370P(NS5A)+S76A(NS5B). We ob-
served that the replicon containing the first triplet lost the ability to
replicate at significant level. For replicons containing the latter two
combinations of mutations, RNA replication could be measured,
although at a lower level compared to the parental construct (35%
and 20%, respectively). These replicons, however, remained
equally sensitive to AL-9 as the parental replicon (Figure S2),
opening the question as to which really is the target of this
compound class. We are currently trying to select HCV replicons
resistant to AL-9. So far we were unable to identify mutations that
confer resistance to AL-9.
Our new data on AL-9 suggest that inhibition of HCV
replication by 4-anilino quinazoline compounds is a consequence
of PI4KIIIa inhibition. Our conclusion rests on a number of
experimental findings. First of all, we showed that AL-9 is an
inhibitor of purified type III PI4 kinases. Furthermore, we clearly
demonstrated that AL-9 inhibits PI4KIIIa both in naı ¨ve Huh7.5
cells (Figure 5, discussed above) as well in cells harboring actively
replicating HCV RNA (Figure 8). In cells where HCV replication
occurs, PI4KIIIa interacts physically with HCV NS5A. This
interaction, in turn, leads to the stimulation of PI4P synthesis at
the HCV replication sites [32]. Treatment of replicon-harboring
cells with AL-9 leads to efficient suppression of the PI4P pool at
the HCV replication sites and does so independently of inhibition
of HCV replication. This indicates that – although the enzymatic
activity of PI4KIIIa is modulated by the interaction with the HCV
protein NS5A – it remains sensitive to the action of the 4-anilino
quinazoline inhibitor.
We also investigated whether the dramatic changes observed in
PI4P membrane levels by treatment with AL-9 could be associated
with alteration in the subcellular distribution of type III PI4
kinases. To this aim, we analyzed the subcellular distribution of the
type III PI4 kinases in Huh7.5 or Luc-A4 cells following
incubation with AL-9 (Figure S3). We observed no major effect
of AL-9 on the localization of either PI4KIIIa or PI4KIIIb, in line
with the notion that the observed effects are primarily due to the
inhibition of the kinase activity rather than to an altered protein
subcellular distribution.
In cells that express the HCV polyprotein from a trans-gene,
knock-down of PI4KIIIa by RNAi was previously shown to cause
a dramatic change in NS5A subcellular distribution, from a
pattern consistent with localization in the membranous web
replication complexes to abnormally large cytoplasmic clusters
[27,30,32]. In Figure 9, we show that AL-9 treatment of cells
ectopically expressing the HCV nonstructural proteins results in a
time-dependent depletion of PI4P and a concomitant change of
NS5A localization to the large-clustered structures discussed
above, reinforcing the notion that the anti-HCV effect of AL-9
and related compounds are likely to be mediated by the inhibition
of PI4KIIIa.
We also found that PI3K p110a is inhibited by AL-9 in vitro at
concentration similar to those needed to inhibit type III PI4-
kinases. However, no Class I PI3-kinase has been shown to
influence HCV replication thus inhibition of HCV replication by
AL-9 is not due to inhibition of Class I PI3-kinases. So far, the only
PI3-kinase that resulted as positive hit for HCV replication
inhibition in siRNA screens is PI3-kinase C2 gamma [28]. Future
work will have to address whether AL-9 inhibits PI3KC2G in
addition to Type III PI4-kinases.
During the characterization of AL-9 we focused our attention
on various aspects of PI4P metabolism in Huh7.5 cells with and
without replicating HCV. We observed a typical Golgi localization
of PI4P in intracellular membranes of naı ¨ve Huh7.5 cells and
confirmed a role for PI4KIIIb in maintaining at least part of this
pool. In order to get the complete picture we also investigated the
PI4P pool present in the plasma membrane. In yeast, Stt4p, the
ortholog to the mammalian PI4KIIIa, is localized at the plasma
membrane and it is the major contributor for the synthesis of the
plasma membrane-localized PI4P [43]. In mammalian cells, the
role of PI4KIIIa for the maintenance of the plasma membrane
PI4P pool has been demonstrated in HEK-293 and Cos-7 cells
[35–37]. Here we demonstrate that liver-derived Huh7.5 cells are
endowed with a rich PI4P pool in the plasma membrane and that
the enzyme responsible for its maintenance is PI4KIIIa. In HCV-
replicating cells, the subcellular PI4P distribution is profoundly
altered. As already reported previously, the presence of HCV
causes the induction of a membranous web highly enriched for
PI4KIIIa-syntesized PI4P. In accordance, several reports demon-
strate that NS5A recruits PI4KIIIa to the membranous web by
direct protein-protein interaction, thereby stimulating its enzy-
matic activity [30–32]. Concomitantly with the induction of highly
PI4P-enriched internal membranes, we observe a marked decrease
of PI4P in the plasma membrane. One possible explanation could
be that – by hijacking PIKIIIa – HCV might be able to enrich
PI4P in the virus-induced membranous web not only by directly
activating the enzymatic activity of PI4KIIIa recruited into the
HCV RNA replication compartment, but also by preventing
transport of the PI4KIIIa-synthesized PI4P from the synthesis site
to the plasma membrane. How PI4KIIIa, localized at the ER,
synthesizes the PI4P pool present in the plasma membrane it is still
an enigma. This topological discrepancy can partially be resolved
assuming that PI4KIIIa-dependent PI4P production occurs on
ER-PM contact sites, that is, sites of close apposition between ER
and PM. In yeast it has been demonstrated that a complex
interplay between different proteins regulate the PI4P metabolism
at the plasma membrane [47]. Among these proteins are Osh, the
yeast ortholog of the human OSBP and the ER membrane VAP
proteins Scs2 and Scs22, the yeast orthologs of human VAP
proteins. Interestingly, h-VAP-33 and OSBP have been shown to
be important for HCV replication [48–50]. It may be possible that
recruitment of PI4KIIIa to the HCV membranous web through
NS5A prevents interaction of PI4KIIIa with its cellular protein
partners required to direct PI4P to the plasma membrane. Upon
withdrawal of HCV from the cells (Figure 7) PI4KIIIa is again free
for interaction with the adequate partners. A possible role of
PI4KIIIa in PI4P trafficking between the plasma- and intracellular
membranes is suggested by our finding that RNAi silencing of this
PI4 kinase results in decreased concentration of PI4P in the plasma
membrane with a concomitant increase in the level of PI4P in the
endomembranes (Figure 3). Such a function of PI4KIIIa would
have to be independent of the kinase activity, since pharmacolog-
ical inhibition (with PIK93 or AL-9) does not recapitulate this
phenomenon observed by knocking down the protein expression.
In summary, the presence of HCV may change PI4P
metabolism not only by activating the catalytic activity of
PI4KIIIa by NS5A but also by modulating the PI4P distribution
between different membrane compartments. The net result is an
enrichment of the PI4P pool in the HCV-induced membranous
web with a concomitant depletion of the plasma membrane PI4P
pool.
Concluding, in this paper we demonstrate that a class of HCV
inhibitors originally proposed to target NS5A does in fact target
the host factor PI4KIIIa. Compounds targeting host factors may
have the general advantage of imposing a higher genetic barrier to
the development of resistance. AL-9, a member of this class of
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compound with a clear preference for PI4KIIIa over PI4KIIIb.
For this reason, AL-9 offers a good candidate as lead compound
for the development of more potent and specific pharmacological
inhibitors of PI4KIIIa to be used both as important research tools
as well as leads for initial drug discovery.
Materials and Methods
Reagents and plasmids
The HCV RNA polymerase inhibitor HCV-796 and the PI
kinase inhibitor PIK93 were a gift from Arrow Pharmaceuticals.
The HCV protease inhibitor MK-5172 was purchased from
Selleck Chemicals. Nucleic acids were manipulated according to
standard protocols. Plasmid FBac-His-CD-PI4KA was constructed
as follows: the catalytic domain of PI4KIIIa was amplified by PCR
using the oligonucleotides 59-CACTGCGGATCCATAATGGG-
GATGATGCAGTGTGTGATTG-39 (sense), 59-CCTGCGAA-
TTCTCAGTAGGGGATGTCATTC-39 (antisense) and the
plasmid pEF1A-PIK4CA untagged (a kind gift from G. Randall,
Department of Microbiology, University of Chicago) as template.
The resulting PCR fragment was subcloned into the vector pCR-
Blunt II-Topo (Invitrogen) and finally cloned into the BamH1–
XhoI cloning sites of the plasmid vector pFastBac THT-B. The
resulting protein expressed from this plasmid contains an N-
terminal hexa-histidine tag and starts at PI4KIIIa amino acid
G873 (reference sequence NM_058004). pTM-NS3-5B expression
vector expressing the HCV genotype 2a nonstructural proteins
under the control of the T7 promoter was a generous gift from V.
Lohmann (Department of Molecular Virology, University of
Heidelberg) [42]. Synthesis of compound AL-9 is described in
Supporting Information.
Cells lines and culture conditions
The human hepatoma-derived cell line Huh7.5 [51] were
grown in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum, 100 U/ml penicillin,
100 mg/ml Streptomycin and 2 mM L-glutamine; G418
(0.8 mg/ml) was added to cell lines containing the HCV replicon.
Stable cell lines expressing HCV genotype 1b or 2a subgenomic
replicons were generated by electroporation of in vitro-transcribed
RNA into Huh7.5 cells [52] and following selection with G418
(0.8 mg/ml) for three weeks. Con1-SR: Huh7.5 cells replicating
the Con1 subgenomic replicon with the adaptive mutations
E1202G in NS3 and S2204R in NS5A. JFH-A4: Huh7.5 cells
replicating the JFH-1 subgenomic replicon together with the
luciferase reporter gene constructed as described previously [53].
JFH-A4 cells were cured from the HCV replicon by two weeks of
treatment with the protease inhibitor MK-5172 (0.2 mM) or the
HCV RNA polymerase inhibitor HCV-796 (2 mM), respectively.
Huh7-Lunet/T7 cells were a kind gift from V. Lohmann
(Department of Molecular Virology, University of Heidelberg,
Germany).
Replication and infection assays
For replication assays, JFH-A4 or Con1-SR cells were plated at
the density of 3610
4 or 6610
4 cells/well, respectively, in 24-well
dishes the day before the experiment. Cells were treated with AL-9
resulting in a final concentration of 1% DMSO in the cell
medium. After three days of treatment, RNA was extracted using
the RNeasy Mini Kit (Qiagen) and HCV RNA was quantified by
real time PCR using the following oligonucleotide and probe set
designed for the HCV IRES as described previously [52]: sense
(59-GCGAAAGGCCTTGTGGTACT-39), antisense (59-CACG-
GTCTACGAGACCTCCC-39), and probe (59-CCTGATAGG-
GTGCTTGCGAGTGCC-39,5 9 6-carboxyfluorescein [FAM]/39
6-carboxytetramethylrhodamine [TAMRA]). GAPDH mRNA
was used as internal control for data normalization.
Production of infectious virus was performed as follows: J6/
JFH-1 chimeric RNA (1-846(J6CF)/847-3034(JFH1) was electro-
porated into Huh7.5 cells using the protocol described previously
[52]. Briefly, 2610
6 cells were electroporated with 10 mg of RNA
in a final volume of 200 ml and 4610
6 cells were plated in a T-75
flask. Three days post electroporation, medium was harvested and
stored at 220uC in small aliquots. Calculation of EC50 of AL-9
using the infectious HCV virus was performed as follows: Huh7.5
cells were plated at 4610
4 cells/well in 24-well plates the day
before infection. Infection was started by addition of 10 ml of cell
medium containing infectious virus (see above) at an MOI of 50 in
a final volume of 400 ml. After 6 hours of incubation, medium was
removed and replaced with 400 ml of fresh medium containing
serial dilutions of AL-9. RNA was collected after 72 hours of
incubation and quantified by real time PCR. Cell cytotoxicity
(CC50) of AL-9 was calculated using the cell viability assay
CellTiter-Blue (Promega). Huh7.5, JFH-A4, or Con1-SR cells
(5610
3 cells/well in 96-well dishes) were plated the day before
treatment. AL-9 was added and cell viability was measured after
four days of treatment.
Expression and purification of the catalytic domain of
PI4KIIIa
Recombinant baculovirus was generated with the plasmid
FBac-His-CD-PI4KA using the Bac-to-Bac system following the
instructions of the manufacturer (Invitrogen). For protein
expression, Sf9 cells were infected with recombinant baculovirus
at a density of 2610
6 Sf9 cells/ml for 3 days at 20uC. To prepare
cell extract (1.5610
8 cells), cells were incubated in hypotonic
buffer (10 mM HEPES (pH 7.5), 10 mM NaCl, 1 mM Tris(2-
carboxyethyl)phosphine (TCEP) and EDTA-free protease inhib-
itor cocktail (Complete, Roche) for 30 min in ice and mechanically
broken by 20 strokes of a Dounce homogenizer. After homoge-
nizing, cells were incubated in lysis buffer (50 mM HEPES
(pH 7.5), 500 mM NaCl, 10% glycerol, 1% Triton-X100, 1 mM
TCEP and EDTA-free protease inhibitor cocktail (Complete,
Roche) for further 30 min in ice and cell extract was cleared by
centrifugation for 45 min at 20.000 g. The cleared supernatant
was incubated in batch with Ni-Sepharose High Performance (GE
Healthcare) for 2 hours at 4uC with continuous shaking. The resin
was first washed with 10 resin-volumes of wash buffer (50 mM
HEPES (pH 7.5), 10% glycerol, 0.4% Triton X-100, 150 mM
NaCl and 20 mM imidazol) followed by elution with wash buffer
containing 250 mM imidazole. Active fraction (0.5 ml) were
dialyzed against 50 mM HEPES (pH 7.5), 150 mM NaCl,
1 mM DTT, 0.4% Triton X-100 and 10% glycerol and stored
at 280uC in small aliquots.
In vitro kinase assay
PI4K kinase activity was assayed with the ADP-Glo Kinase
Assay (Promega), according to the manufacturer’s instructions.
Briefly, 0.5 ml of PI4KIIIa-CD or 0.05 ml PI4KIIIb (32 ng,
Invitrogen) were preincubated with DMSO or AL-9 in reaction
buffer (20 mM Tris (pH 7.5), 5 mM MgCl2, 2 mM DTT, 0.5 mM
EGTA, 0.4% Triton X-100) for 10 min at room temperature in a
final volume of 8 ml. The reaction was started by addition of 2 ml
of ATP and PI:PS Lipid Kinase Substrate (Invitrogen) to give a
final concentration of 100 mM and 150 mM, respectively. After
1 hour of incubation at room temperature the reaction was
stopped and further processed as described by the manufacturer.
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order to detect contaminating ATPase activity present in the
protein fractions. This activity was subtracted from the measured
kinase activity. Kinase activity of PI3Ka (p110a/p85a) and PI3Kb
(p110b/p85a) was assayed as above using 5 ng or 20 ng,
respectively (Millipore). Reaction buffer was changed to 50 mM
HEPES pH 7.5, 10 mM MgCl2 and 1 mM DTT.
Indirect immunofluorescence
Cells were plated one day before the experiment in 24-well
plates (5610
4 cells/well for Huh7.5 and JFH-A4 cells, 7610
4
cells/well for Con1-SR and 1610
5 cells/well for cured JFH-A4
cells). Cells were either untreated or treated with compounds for
the time as indicated in the figure legend. PI4P staining of the
plasma membrane or internal membranes was performed exactly
as described previously [37]. Primary antibodies used were: anti-
PI4P IgM (Cat.No. Z-P004, 1:300, Echelon), anti-Giantin anti-
body (Cat. No. PRB-114C-200 1:1000, Covance), affinity-purified
rabbit anti-NS5A antibody (1:2000) [54], anti-PI4KIIIa kinase
(Cat. No. 4902, 1:50, Cell Signaling), anti-PI4KIIIb kinase (Cat.
No, 611817, 1:500, BD Transduction). Secondary antibodies used
were goat anti-mouse IgM Alexa Fluor 488 (Cat. No. A-21042,
1:600, Invitrogen) and goat anti-rabbit Alexa Fluor 568 (Cat.-
No. A-11011, 1:600, Invitrogen). For type III PI4K kinases or
NS5A staining, all incubations were performed at room temper-
ature. Cells were washed once with PBS and fixed with 300 mlo f
4% PFA for 15 min. Cells were washed three times with PBS and
permeabilized with 500 ml of 0.1% Triton X-100 (or 0.5% for
PI4KIIIa kinase staining) in PBS for 10 min. Unspecific binding
was blocked by incubation with 3% BSA in PBS (for PI4KIIIa
staining no blocking was performed). After incubation with the
primary antibody in blocking buffer, cell were washed with PBS
and subsequently incubated with goat secondary antibodies
conjugated to Alexa-Fluor 568, or Alexa-Fluor 488 at a dilution
of 1:600. Nuclei were stained with Hoechst dye 33342 (Sigma;
1:4000). Slides were then mounted with 5 ml ProLong Gold
Antifade (Invitrogen) and analyzed by using an inverted Leica
TCS SP5 scanning laser confocal microscope. Digital images were
taken using LAS AF software (Leica) and processed using Volocity
software (Perkin Elmer). Quantification of fluorescence intensity
was determined from multiple images using Volocity. Relative
changes in fluorescence intensity mean values where obtained
from four randomly picked fields for each condition (150,300
cells). For plasma membrane staining, total PI4P fluorescence
intensity obtained in each condition was normalized to the
number of cells present in each field. For the quantification of
relative PI4P levels in internal membranes, PI4P fluorescence
intensity was normalized using the fluorescence intensity of the
Golgi marker giantin. Quantitative immunofluorescence data are
presented as means 6 the standard error of the mean (SEM). For
the calculation of statistical significance, a two-tailed, unpaired t-
test was performed.
siRNA silencing
3610
4 Huh7.5 cells/well were seeded in 24-well plates on
microscope cover glasses and transfected with 50 nM of siRNAs in
serum-free Opti-MEM (Invitrogen) using Lipofectamine RNAi-
MAX (Invitrogen), according to the manufacturer’s protocol. For
western blot analysis, the transfection reaction was proportionally
scaled up to 6-well plates. In order to maximize the silencing
efficiency, 24 hours after the first transfection, the cells were
subjected to a second round of siRNA transfection. siRNA
sequences were the following (59R39 sense strand): mock siRNA,
59-GUAUGACCGACUACGCGUA[dT][dT]-39 (custom, Sigma-
Aldrich); PI4KIIIa siRNA, 59-CCGCCAUGUUCUCAGAU-
AA[dT][dT]-39 (custom, Sigma-Aldrich); and PI4KIIIb siRNA,
59-GCACUGUGCCCAACUAUGA[dT][dT]-39 (Silencer Vali-
dated siRNA s10543; Ambion). Three days after the initial
transfection, cells were stained for PI4P as described previously
[37], or subjected to western blot analysis. For immunoblot analysis
of proteinexpression,cellswereharvested withTENbuffer(10 mM
Tris/HCl pH 8.0, 1 mM EDTA, 100 mM NaCl), washed once
with PBS and lysed with 2X protein sample buffer (125 mM Tris-
HCl pH 6.8, 10 mM EDTA, 0,003 gr bromophenol blue, 20%
glycerol, 4% SDS and 10% b-mercaptoethanol; 200 ml). The
samples were then sonicated, heated at 95uC and loaded onto 7.5%
polyacrylamide-SDS page (Criterion, Biorad). After electrophoresis
proteins were transferred to a nitrocellulose membrane and
unspecific binding was blocked by PBS supplemented with 0.5%
Tween (PBS-T) and 5% milk. Membranes were then incubated
overnight at 4uC with primary antibodies (anti-PI4KIIIa, cat
no. 4902, 1:250 Cell Signaling, anti-PI4KIIIb, cat. No. 611817,
1:3000 BD Transduction Laboratories, mouse anti-b-actin, cat.
No. A1978, 1:5000, Sigma). HRP-conjugated secondary antibodies
(donkey anti-rabbit, Cat. No. 9341 and sheep anti-mouse, Cat.
No. 9311, GE Healthcare) were incubated for 1 hour at room
temperatureanddetectionwasperformed usingSuperSignal-Femto
chemiluminescent substrate (Pierce-Thermo Scientific).
T7-driven HCV polyprotein expression
1.5610
6 Huh7-Lunet/T7 cells/100 mm dish were transfected
with 20 mg pTM-NS3-5B using the transfection reagent Lipofec-
tamine 2000 (Invitrogen). Six hours after transfection, cells were
seeded in 24-well plates on microscope cover glasses for indirect
immunofluorescence. After 5 hours, cells were treated either with
DMSO or with 8 mM AL-9 for 2, 8 or 16 hours and co-staining of
NS5A and PI4P was performed using the Golgi staining protocol,
as described previously [37].
Supporting Information
Figure S1 Synthetic pathway for compound AL-9. Re-
agents and conditions: (a) n-BuLi, dry THF, 278uC 1 h, 20uC
3h ,B u 3SnCl, 278uC 2 h, RT overnight; (b) Formamide, 155uC,
16 h; (c) SOCl2, dry DMF, reflux, 5 h, 4-morpholinoaniline, dry
CH3CN, reflux, 16 h; (d) compound 1, bis(triphenylphosphine)
palladiumdichloride,dryTHF,reflux;(e)HCl2M,THF/H2O1:1 ,
RT; (f) NaBH(OAc)3,C H 2Cl2/AcOH (15:1), RT.
(TIF)
Figure S2 HCV replicons harboring putative 4-anilino
quinazoline resistance mutations retain sensitivity to
inhibition by AL-9. Huh7.5 cells where transiently transfected
with genotype 1b subgenomic replicons carrying mutation triplets
reported to be associated to resistance to 4-anilino quinazolines
(ET-FAG, ET-PPA or ET-DLD) or with the parental replicon
(ET). The ET replicon is a derivative of the Con-1 replicon that
contains adaptive mutations at positions E1202G, T1280I, and
K1846T [1], i.e, the same genetic background used in the original
resistance study [2]. The putative resistance mutations triplets
engineered in this replicon were as follows: ET-FAG (L199F,
V362A, S390G in NS5A); ET-PPA (T200P, S370P in NS5A and
S76A in NS5B); ET-DLD (E212D, P299L, V388D in NS5A).
Transfected cells were treated with AL-9 for three days. Inhibitory
dose-response curve of AL-9 are shown. Transient HCV
replication was measured by Luciferase activity and is expressed
as % of the DMSO control. The data are averages from of three
experimental replicates. EC50 values +/21 SD are shown in the
Anilino Quinazoline HCV Inhibitors Target PI4KIIIa
PLoS Pathogens | www.plospathogens.org 15 March 2012 | Volume 8 | Issue 3 | e1002576figure inset. Replicon ET-FAG did not replicate at appreciable
levels.
(TIF)
Figure S3 Effect of AL-9 on subcellular distribution of
type III PI kinases. Cellular localization of PI4KIIIa (green),
PI4KIIIb (green) or NS5A (red) was analyzed by immunofluores-
cence in Huh7.5 or JFH-4A cells incubated for 4 hrs with 8 mM
AL-9 or DMSO (control). Zoomed sections are indicated by a
white square. No major effect of AL-9 on the localization of either
PI4KIIIa or PI4KIIIb was observed. Under our experimental
conditions, we observe very limited colocalization of PI4KIIIa
with NS5A (yellow) independent of the treatment with AL-9.
(TIF)
Protocol S1 Chemical synthesis of compound AL-9.
(DOC)
Protocol S2 Construction and assays of HCV replicons
harboring putative resistance mutations.
(DOC)
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